ENDRA Life Sciences Inc
NASDAQ:NDRA
ENDRA Life Sciences Inc
Stock-Based Compensation
ENDRA Life Sciences Inc
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ENDRA Life Sciences Inc
NASDAQ:NDRA
|
Stock-Based Compensation
$421.2k
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Stock-Based Compensation
$299m
|
CAGR 3-Years
11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
11%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Stock-Based Compensation
$158.1m
|
CAGR 3-Years
8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
12%
|
|
|
Stryker Corp
NYSE:SYK
|
Stock-Based Compensation
$243m
|
CAGR 3-Years
13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Stock-Based Compensation
$664m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Stock-Based Compensation
$788.2m
|
CAGR 3-Years
15%
|
CAGR 5-Years
15%
|
CAGR 10-Years
17%
|
|
ENDRA Life Sciences Inc
Glance View
ENDRA Life Sciences, Inc. develops medical imaging technology. The company is headquartered in Ann Arbor, Michigan and currently employs 22 full-time employees. The company went IPO on 2017-06-28. The firm has developed a technology platform, Thermo Acoustic Enhanced Ultrasound (TAEUS), which is intended to enhance the capability of clinical ultrasound technology and support the diagnosis and treatment of various other medical conditions. Its TAEUS technology platform application focuses on quantifying fat in the liver and stage progression of non-alcoholic fatty liver disease (NAFLD), which untreated, can progress to Non-alcoholic Steatohepatitis (NASH), fibrosis, cirrhosis, and liver cancer. The firm's TAEUS platform has various clinical applications, such as tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.
See Also
What is ENDRA Life Sciences Inc's Stock-Based Compensation?
Stock-Based Compensation
421.2k
USD
Based on the financial report for Sep 30, 2025, ENDRA Life Sciences Inc's Stock-Based Compensation amounts to 421.2k USD.
What is ENDRA Life Sciences Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
-31%
Over the last year, the Stock-Based Compensation growth was -41%. The average annual Stock-Based Compensation growth rates for ENDRA Life Sciences Inc have been -32% over the past three years , -31% over the past five years .
